Furthermore, the expression of an oncogenic variant of KRAS is closely associated with a marked increase in glycolytic activity199, 200 within the cells,201 thereby substantiating a metabolic reprogramming that fosters an environment conducive to tumor cell proliferation and survival. The gene discussed is KRAS; the disease is neoplasm.